Literature DB >> 30697137

Tolvaptan Use to Treat SIADH in a Child.

Adem Yasin Koksoy, Meltem Kurtul, Aslı Kantar Ozsahin, Fatma Semsa Cayci, Meltem Tayfun, Umut Selda Bayrakci.   

Abstract

Hyponatremia is one of the most common electrolyte abnormalities encountered in the clinical setting in hospitalized patients. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the leading cause of hyponatremia in most of these cases. While fluid restriction, hypertonic saline infusion, diuretics, and the treatment of underlying conditions constitute the first line of treatment of SIADH, in refractory cases, and especially for pediatric patients, there seems not to be any other choice for treatment. Tolvaptan, although its use in pediatric patients is still very limited, might be an attractive treatment option for correction of hyponatremia due to SIADH. Here we present a pediatric case of SIADH that was resistant to treatment with fluid restriction and hypertonic saline infusion and was treated successfully with tolvaptan. Tolvaptan could be a good, safe, and effective treatment option in pediatric SIADH cases that are resistant to treatment. However, the dosage should be titrated carefully.

Entities:  

Keywords:  SIADH; case report; child; hyponatremia; pediatric; tolvaptan; treatment

Year:  2018        PMID: 30697137      PMCID: PMC6336180          DOI: 10.5863/1551-6776-23.6.494

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  17 in total

1.  Clinical practice guideline on diagnosis and treatment of hyponatraemia.

Authors:  Goce Spasovski; Raymond Vanholder; Bruno Allolio; Djillali Annane; Steve Ball; Daniel Bichet; Guy Decaux; Wiebke Fenske; Ewout J Hoorn; Carole Ichai; Michael Joannidis; Alain Soupart; Robert Zietse; Maria Haller; Sabine van der Veer; Wim Van Biesen; Evi Nagler
Journal:  Nephrol Dial Transplant       Date:  2014-02-25       Impact factor: 5.992

Review 2.  Evaluation and management of hyponatraemia in children.

Authors:  Jakub Zieg
Journal:  Acta Paediatr       Date:  2014-07-01       Impact factor: 2.299

3.  Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.

Authors:  Joseph G Verbalis; Steven R Goldsmith; Arthur Greenberg; Cynthia Korzelius; Robert W Schrier; Richard H Sterns; Christopher J Thompson
Journal:  Am J Med       Date:  2013-10       Impact factor: 4.965

4.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Authors:  Robert W Schrier; Peter Gross; Mihai Gheorghiade; Tomas Berl; Joseph G Verbalis; Frank S Czerwiec; Cesare Orlandi
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

5.  Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.

Authors:  Pornpimol Rianthavorn; Joan P Cain; Martin A Turman
Journal:  Pediatr Nephrol       Date:  2008-04-24       Impact factor: 3.714

Review 6.  Urinary concentration: different ways to open and close the tap.

Authors:  Detlef Bockenhauer; Daniel G Bichet
Journal:  Pediatr Nephrol       Date:  2013-06-06       Impact factor: 3.714

7.  Tolvaptan therapy for massive edema in a patient with nephrotic syndrome.

Authors:  Masaki Shimizu; Sayaka Ishikawa; Yusuke Yachi; Masahiro Muraoka; Yuko Tasaki; Hidenori Iwasaki; Mondo Kuroda; Kazuhide Ohta; Akihiro Yachie
Journal:  Pediatr Nephrol       Date:  2013-11-19       Impact factor: 3.714

8.  Nephrogenic syndrome of inappropriate antidiuresis.

Authors:  D Morin; J Tenenbaum; B Ranchin; T Durroux
Journal:  Int J Pediatr       Date:  2012-02-28

9.  Vaptans: A new option in the management of hyponatremia.

Authors:  Suruchi Aditya; Aditya Rattan
Journal:  Int J Appl Basic Med Res       Date:  2012-07

10.  The role of v2 receptor antagonists in the treatment of hyponatremia.

Authors:  Biff F Palmer
Journal:  Electrolyte Blood Press       Date:  2013-06-30
View more
  2 in total

Review 1.  Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?

Authors:  Fei Liu; Chunyue Feng; Huijun Shen; Huaidong Fu; Jianhua Mao
Journal:  Kidney Dis (Basel)       Date:  2021-07-02

2.  Case Report: Long-Term Tolvaptan Treatment in a Child With SIADH and Suprasellar Arachnoid Cyst.

Authors:  Andrea Puma; Milena Brugnara; Paolo Cavarzere; Marco Zaffanello; Giorgio Piacentini; Rossella Gaudino
Journal:  Front Pediatr       Date:  2021-07-16       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.